华东医药：2026年第一季度报告（英文版）

HuadongMedicineCo.,Ltd.FirstQuarterlyReport2026 TheCompanyandallmembersoftheBoardofDirectorsherebyguaranteethattheinformationpresentedinthisreportisauthentic,accurateandcompleteandfreeofanyfalserecords,misleadingstatementsormaterialomissions. ImportantDeclaration: 1.TheBoardofDirectors,directorsandseniormanagementofHuadongMedicineCo.,Ltd.(hereinafterreferredtoasthe"Company")herebyguaranteethattheinformationpresentedintheReportisauthentic,accurateandcompleteandfreeoffalserecords,misleadingstatementsormaterialomissions,andshallundertakeindividualandjointlegalliabilities. 2.TheCompany'slegalrepresentative,theofficerinchargeofaccounting,andtheheadofAccountingDepartment(accountingmanager)herebydeclarethatthefinancialinformationinthisquarterlyreportisauthentic,accurateandcomplete. 3.HastheFirstQuarterlyReportbeenaudited? □YesNo Accordingto“StockListingRulesoftheShenzhenStockExchange”,iflistedcompanieshavebothChineseandotherlanguageversionofpublicnotice,theyshouldensurethecontentofbothversionsarethesame.Inthecaseofdiscrepancy,theoriginalversioninChineseshallprevail. I.KeyFinancialData (I)Keyaccountingdataandfinancialindicators WhethertheCompanyneedstoperformaretroactiveadjustmentorrestatementofpreviousaccountingdata□YesNo TheCompany'stotalsharecapitalasofthetradingdaypriortodisclosure: Fullydilutedearningspersharebasedonthelatestsharecapital: (II)Non-recurringprofitandlossitemsandamounts Applicable□Notapplicable Unit:RMB Therearenootherprofitandlossitemsthatmeetthedefinitionofnon-recurringprofitsandlosses. Explanationforrecognizinganitemlistedasanon-recurringprofitandlossintheInterpretativeAnnouncementNo.1onInformationDisclosureCriteriaforPublicListedCompanies-Non-RecurringProfitsandLossesasanitemofrecurringprofitandloss □ApplicableNotapplicableTheCompanydidnotrecognizeanyitemofnon-recurringprofitandlossitemslistedintheInterpretativeAnnouncementNo.1on InformationDisclosureCriteriaforPublicListedCompanies-Non-RecurringProfitsandLossesasanitemofrecurringprofitandloss. (III)Detailsandreasonsforchangesinkeyaccountingdataandfinancialindicators Applicable□Notapplicable Unit:RMB10,000 II.ShareholderInformation (I)Totalnumberofcommonshareholders,numberofpreferredshareholderswithrestoredvotingrightsandshareholdingsoftop10shareholders Unit:Shares Participationinthelendingofsharesthroughrefinancingbusinessofshareholdersholdingmorethan5%ofshares,top10shareholdersandtop10shareholdersholdingtradableshareswithouttradingrestriction □ApplicableNotapplicable Changeintop10shareholdersandtop10shareholdersholdingtradableshareswithouttradingrestrictionduetolending/returningofsharesthroughrefinancingascomparedtothepreviousperiod □ApplicableNotapplicable (II)Totalnumberofpreferredshareholdersandshareholdinglistoftop10preferredshareholdersoftheCompany □ApplicableNotapplicable Ⅲ.OtherImportantMatters Applicable□Notapplicable (I)OverviewoftheCompany'soveralloperationsduringthereportingperiod In2026,externalcompetitionisexpectedtocontinueintensifying,andthepolicyenvironmenthasbecomeincreasinglycomplexandvolatile.Corporatedevelopmentfacesmountingpressures.Competitiondrivenbymarketsharewillenteranewstage.Duringthereportingperiod,inthefaceofthesechallenges,theCompanyhasremainedfirmlyalignedwithitsoverallstrategicroadmapandannualoperationalobjectives.Guidedbythebusinessprioritiesof"exploringnewmarkets,focusingon new products,strengthening organizational capabilities,and building newcompetencies",theCompanyhasupheldthemanagementphilosophyof"problem-solvingandvaluecreation",and integrated the principles of"innovation-driven development,resourceintegration,and enterprise-wide collaboration"throughout all operational processes;stayingcommittedtoitsinnovation,theCompanyhassystematicallyadvancedcomprehensiveupgradesacrossitsproductportfolio,managementsystems,andtalentdevelopment.ItconcentratedresourcesontacklingkeyR&Dandclinicalstudyprograms,deepenedcollaborationacrosssectorssuchaspharmaceuticals,medicalaesthetics,andcommercial operations,continuouslyactivatedgrowthdriversfor innovative business,and realized steady improvements in operational quality andmanagementefficiency,ensuringtheorderlyexecutionofvarioustasks. Duringthereportingperiod,theCompanyachievedoperatingrevenueofRMB11.183billion,representingaYoYincreaseof4.17%andaquarter-on-quarterincreaseof2.15%comparedwithQ42025.NetprofitattributabletoshareholdersofthelistedcompanyreachedRMB1.002billion,up9.56%year-on-year.Netprofitattributabletoshareholdersexcludingnon-recurringprofitandlossitemswasRMB990million,markingaYoYincreaseof10.30%andreachingahistoricalhighforthesameperiod. Duringthereportingperiod,ZhongmeiHuadong,theCompany'scoresubsidiaryinthefieldofpharmaceuticalindustry,maintainedsteadygrowthinoverall operations.Itachievedoperatingrevenue(includingCSObusiness)ofRMB4.048billion,representingan11.82%YoYincrease.Theconsolidated netprofit attributable totheparentcompany reached RMB 931million,up10.44%year-on-year.Bothoperatingrevenueandnetprofitattr